White Paper

COVID-19 Vaccination and Coverage under Workers’ Compensation

The continuing rollout of the COVID-19 vaccine, while welcome, brings questions regarding coverage that is new to the workers’ compensation pharmaceuticals field.
By:

White Paper Summary

This is an emerging and evolving topic that the entire myMatrixx team is keeping a close eye on. To provide essential information about the vaccine, drug therapy in general, and the most up-to-date formulary considerations, we recently released a whitepaper sharing the myMatrixx position on Position Paper regarding COVID-19 Vaccination and Coverage under Workers’ Compensation.

The paper provides an overview of the cost of the vaccine, associated administration fees, reimbursement guidelines, formulary considerations and efficacy rates, particularly as they may apply to the workforce. There are also sections covering herd immunity, the emergence of new COVID-19 strains and vaccine availability as these continue to be significant areas of concern around the pandemic.

Register to download the full content

 

To learn more about myMatrixx, please visit their website.

myMatrixx® is a pharmacy benefit management company dedicated to workers’ compensation and uniquely able to deliver customized solutions and high touch customer service. For more information, visit myMatrixx.com.

More from Risk & Insurance

More from Risk & Insurance